You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023539030
Dec 20238909
Jan 20246805
Feb 20244804
Mar 20243203
Apr 202470011
May 20246607
Jun 20243606
Jul 20244203
Aug 20247007
Sep 20243608
Oct 202448011
Nov 202498019
Dec 202478011
Jan 202552010
Feb 202510013
Mar 20250023
Apr 2025003
May 2025009
Jun 2025005
Total13820197